Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Elias HK, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E. Bernard E, et al. Among authors: kotsianidis i. Nat Med. 2020 Oct;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z. Epub 2020 Aug 3. Nat Med. 2020. PMID: 32747829 Free PMC article.
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P. Park S, et al. Among authors: kotsianidis i. J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28. J Clin Oncol. 2017. PMID: 28350519 Free article.
The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. Papageorgiou SG, et al. Among authors: kotsianidis i. Am J Hematol. 2018 Jul;93(7):895-901. doi: 10.1002/ajh.25111. Epub 2018 May 16. Am J Hematol. 2018. PMID: 29659040 Free article.
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. Papageorgiou SG, et al. Among authors: kotsianidis i. Hematol Oncol. 2018 Oct;36(4):693-700. doi: 10.1002/hon.2551. Epub 2018 Sep 7. Hematol Oncol. 2018. PMID: 30129144
The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.
Diamantopoulos P, Koumbi D, Kotsianidis I, Pappa V, Symeonidis A, Galanopoulos A, Zikos P, Papadaki HA, Panayiotidis P, Dimou M, Hatzimichael E, Vassilopoulos G, Delimpasis S, Mparmparousi D, Papageorgiou S, Variami E, Kyrtsonis MC, Megalakaki A, Kotsopoulou M, Repousis P, Adamopoulos I, Kontopidou F, Christoulas D, Kourakli A, Tsokanas D, Konstantinos Papoutselis M, Kyriakakis G, Viniou NA; Hellenic MDS study group. Diamantopoulos P, et al. Among authors: kotsianidis i. Cancer Med. 2019 May;8(5):2056-2063. doi: 10.1002/cam4.2090. Epub 2019 Mar 21. Cancer Med. 2019. PMID: 30897290 Free PMC article.
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.
de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, Symeonidis A, Cermâk J, Hellström-Lindberg E, Stauder R, Sanz G, Mittelman M, Holm MS, Malcovati L, Mądry K, Germing U, Tatic A, Savic A, Almeida AM, Gredelj-Simec N, Guerci-Bresler A, Beyne-Rauzy O, Culligan D, Kotsianidis I, Itzykson R, van Marrewijk C, Blijlevens N, Bowen D, de Witte T; EUMDS Registry Participants. de Swart L, et al. Among authors: kotsianidis i. Haematologica. 2020 Mar;105(3):632-639. doi: 10.3324/haematol.2018.212217. Epub 2019 Jun 6. Haematologica. 2020. PMID: 31171638 Free PMC article.
Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.
Lamprianidou E, Zoulia E, Bernard E, Kordella C, Papoutselis M, Bezirgiannidou Z, Vrachiolias G, Papaemmanuil E, Kotsianidis I. Lamprianidou E, et al. Among authors: kotsianidis i. Leuk Lymphoma. 2019 Dec;60(13):3277-3281. doi: 10.1080/10428194.2019.1627542. Epub 2019 Jun 12. Leuk Lymphoma. 2019. PMID: 31185765 No abstract available.
Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.
Kazachenka A, Young GR, Attig J, Kordella C, Lamprianidou E, Zoulia E, Vrachiolias G, Papoutselis M, Bernard E, Papaemmanuil E, Kotsianidis I, Kassiotis G. Kazachenka A, et al. Among authors: kotsianidis i. Genome Med. 2019 Dec 23;11(1):86. doi: 10.1186/s13073-019-0707-x. Genome Med. 2019. PMID: 31870430 Free PMC article.
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective.
De Witte T, Malcovati L, Fenaux P, Bowen D, Symeonidis A, Mittelman M, Stauder R, Sanz G, Čermák J, Langemeijer S, Hellström-Lindberg E, Germing U, Skov Holm M, Mądry K, Tatic A, Medina Almeida A, Savic A, Mandac Rogulj I, Itzykson R, Hoeks M, Gravdahl Garelius H, Culligan D, Kotsianidis I, Ades L, Van de Loosdrecht AA, Van Marrewijk C, Yu G, Crouch S, Smith A. De Witte T, et al. Among authors: kotsianidis i. Haematologica. 2020 Nov 1;105(11):2516-2523. doi: 10.3324/haematol.2020.266817. Haematologica. 2020. PMID: 33054132 Free PMC article. No abstract available.
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Komrokji R, Steensma D, Balleari E, Götze KS, Kotsianidis I, Guerci-Bresler A, Stamatoullas A, Sanz GF, Germing U, Fenaux P. Park S, et al. Among authors: kotsianidis i. Leuk Res. 2020 Dec;99:106472. doi: 10.1016/j.leukres.2020.106472. Epub 2020 Nov 5. Leuk Res. 2020. PMID: 33212326 No abstract available.
139 results